• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Why Alkermes (ALKS) Is Down 7.4% After Q2 Profit Drop And New Equity Shelf Filing

    Simply Wall St·08/01/2026 08:20:58
    语音播报
    • In late July 2026, Alkermes plc reported second-quarter 2026 results showing revenue of US$496.01 million versus US$390.66 million a year earlier, while net income fell sharply to US$0.501 million from US$87.1 million, alongside an update that no shares were repurchased in the quarter under its completed US$227.99 million buyback program.
    • On the same day, Alkermes filed a US$311.11 million shelf registration for 5,900,000 ordinary shares linked to its employee share plans, highlighting a shift from recent capital returns toward maintaining flexibility to issue equity for compensation and potential financing needs.
    • With Alkermes’ latest quarterly earnings revealing sharply lower profitability, we’ll now examine how this affects its earlier investment narrative and risk balance.

    The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

    Alkermes Investment Narrative Recap

    To own Alkermes, you need to believe its core psychiatry portfolio and orexin pipeline can translate growing revenue into sustainable profits. The latest quarter complicates that story: revenue rose strongly, but net income nearly vanished and the first half swung to a loss, while no shares were repurchased and a new shelf registration was filed. Together, these developments point to profitability and capital allocation as the key short term catalyst and risk.

    The US$311.11 million shelf registration covering 5,900,000 ordinary shares tied to employee plans is particularly relevant here. Coming right after a quarter with minimal net income and no buybacks, it sits alongside rising R&D needs for alixorexton and other programs. For investors focused on near term earnings stabilization as the main catalyst, this added equity flexibility underscores how sensitive the story is to margin recovery and cost discipline.

    Yet against this backdrop, there is a less obvious risk investors need to be aware of around one time items and how they could suddenly reverse...

    Read the full narrative on Alkermes (it's free!)

    Alkermes' narrative projects $2.1 billion revenue and $264.8 million earnings by 2029.

    Uncover how Alkermes' forecasts yield a $47.69 fair value, a 3% downside to its current price.

    Exploring Other Perspectives

    ALKS 1-Year Stock Price Chart
    ALKS 1-Year Stock Price Chart

    Before this earnings miss, the most optimistic analysts were assuming revenue could reach about US$2.8 billion and earnings US$813.0 million by 2029, painting a far more upbeat picture than the current margin pressure suggests. Your view on whether this new profitability wobble and the highlighted pricing and reimbursement risks meaningfully challenge that optimism will shape how you weigh these very different narratives.

    Explore 5 other fair value estimates on Alkermes - why the stock might be worth 22% less than the current price!

    The Verdict Is Yours

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Searching For A Fresh Perspective?

    Every day counts. These free picks are already gaining attention. See them before the crowd does:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.